Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: Vosaroxin
Drug: Decitabine

First Posted Date: 2013-07-09

Last Posted Date: 2022-02-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 66

Registration Number: NCT01893320

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer

Phase 3

Active, not recruiting

Conditions: Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7

Interventions: Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Radiation: Proton Beam Radiation Therapy
Radiation: Photon Beam Radiation Therapy
Other: Quality-of-Life Assessment

First Posted Date: 2013-07-09

Last Posted Date: 2025-03-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 440

Registration Number: NCT01893307

Locations: 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States

and more 19 locations

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1

Completed

Conditions: FLT3 Gene Mutation Negative
Recurrent Acute Myeloid Leukemia
Recurrent Chronic Myelomonocytic Leukemia
Refractory Acute Myeloid Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Chronic Myelomonocytic Leukemia
FLT3 Internal Tandem Duplication Positive
Refractory Myelodysplastic Syndrome

Interventions: Drug: Azacitidine
Drug: Cytarabine
Drug: Quizartinib

First Posted Date: 2013-07-04

Last Posted Date: 2025-04-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 73

Registration Number: NCT01892371

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Bortezomib

First Posted Date: 2013-07-03

Last Posted Date: 2018-04-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT01891968

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Phase 1

Terminated

Conditions: Leukemia

Interventions: Drug: Moxetumomab Pasudotox

First Posted Date: 2013-07-03

Last Posted Date: 2023-10-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT01891981

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: CD20 Positive
CCND1 Positive
CCND2 Positive
CCND3 Positive
Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma

Interventions: Drug: Ibrutinib
Other: Laboratory Biomarker Analysis
Biological: Rituximab

First Posted Date: 2013-06-19

Last Posted Date: 2025-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 113

Registration Number: NCT01880567

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Selective Image Guided Resection of Axillary Lymph Nodes

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Procedure: Fine Needle Aspiration (FNA)
Procedure: Ultrasound
Procedure: Breast Surgery + Lymph Node Removal

First Posted Date: 2013-06-19

Last Posted Date: 2015-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17

Registration Number: NCT01880645

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Phase 1

Terminated

Conditions: Leukemia
Myeloma
Myeloproliferative Diseases

Interventions: Drug: Fludarabine
Drug: Melphalan
Drug: Alemtuzumab
Procedure: Stem Cell infusion
Drug: Tacrolimus
Drug: Mini Methotrexate
Drug: G-CSF
Procedure: Donor Lymphocyte Infusion (DLI)
Drug: AP1903
Drug: Methylprednisolone
Behavioral: Questionnaire

First Posted Date: 2013-06-11

Last Posted Date: 2019-07-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT01875237

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

Phase 1

Withdrawn

Conditions: Liver Cancer

Interventions: Other: TheraSphere
Drug: Everolimus
Other: Phone Call

First Posted Date: 2013-05-29

Last Posted Date: 2014-07-22

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01864070

Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea

Phase 2

Completed

Conditions: Advanced Cancers

Interventions: Drug: Fentanyl Buccal Tablet
Other: Placebo Buccal Tablet
Behavioral: Questionnaires

First Posted Date: 2013-05-17

Last Posted Date: 2020-09-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT01856114

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy